India Pharma 2020: Trends That Can Change Business Tempo
Scrip delves into some key trends that could play out in 2020 to shape and impact Indian pharmaceutical firms. Keep an eye on opportunities in key markets like China and the US, and on private equity interest in “control deals” and trade margin-related tweaks on the Indian market.
You may also be interested in...
A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.
Indian companies should post “healthy” growth in 2020, helped by a robust domestic market and abating US pricing pressures, analysts say.
Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.